Evidence map›Paper›PMID 39343941›Full record

ReviewClinical diabetes and endocrinology2024

Serum kisspeptin as a promising biomarker for PCOS: a mini review of current evidence and future prospects.

Emmanuel Kokori, Gbolahan Olatunji, Rosemary Komolafe, Ikponmwosa Jude Ogieuhi, Bonaventure Ukoaka, Irene Ajayi, Nicholas Aderinto

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical diabetes and endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Emmanuel KokoriDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Gbolahan OlatunjiDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Rosemary KomolafeDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Ikponmwosa Jude OgieuhiSiberian State Medical University, Tomsk, Russia.
Bonaventure UkoakaDepartment of Internal Medicine, Asokoro District Hospital, Abuja, Nigeria.
Irene AjayiDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Nicholas AderintoDepartment of Medicine and Surgery, Ladoke Akintola University of Technology, Old Oyo/ Ilorin Rd, P.M.B 4000, Ogbomosho, Oyo-State, 210214, Nigeria. Nicholasoluwaseyi6@gmail.com.ORCID http://orcid.org/0000-0003-0004-7389

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder affecting women of reproductive age, characterised by its multifactorial nature and intricate interplay of genetic, hormonal, and environmental factors. As the search for reliable biomarkers intensifies, serum kisspeptin emerges as a promising candidate due to its central role in regulating the hypothalamic-pituitary-gonadal (HPG) axis. This review aims to consolidate the evolving understanding of kisspeptin as a potential PCOS biomarker, comprehensively exploring its physiological basis, diagnostic challenges in PCOS, and clinical implications. Diagnostic challenges in PCOS are addressed, underscoring the limitations of current criteria and the need for objective and standardised biomarkers. Kisspeptin's introduction as a potential biomarker brings forth both promises and challenges in terms of its diagnostic utility. The review recognises the importance of standardisation in research methodologies and emphasises the exploration of genetic polymorphisms to enhance kisspeptin's robustness as a diagnostic tool.

Indexed as

BiomarkerHypothalamic-pituitary-gonadal (HPG) axisKisspeptinPolycystic ovary syndrome (PCOS)

Identifiers

PMID39343941
PMCPMC11440685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.